Search - tctmd.com

Displaying 481 - 500 of 522

Sort: Relevancy | Date

News Daily News

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

October 19, 2012

News Daily News

El Apixaban tiene el Mismo Riesgo Hemorrágico que la Aspirina en Pacientes con FA

L.A. McKeown

October 10, 2012

News Daily News

Apixaban Matches Bleeding Risk of Aspirin in A-fib Patients

L.A. McKeown

October 10, 2012

News Daily News

El Apixaban Supera a la Warfarina a Todos los Niveles de Riesgo en Pacientes con FA

Caitlin E. Cox

October 04, 2012

News Daily News

Apixaban Surpasses Warfarin At All Risk Levels in A-Fib Patients

Caitlin E. Cox

October 04, 2012

News Daily News

JACC Viewpoint: Studies Needed on Long-term Consequences of ‘Silent’ Cerebral Infarcts

L.A. McKeown

October 03, 2012

News Daily News

Dabigatran Usage up, Both for A-fib and Off-Label Indications

September 12, 2012

News Daily News

No Safe Window for Triple Antithrombotic Therapy in High-Risk A-fib Patients

August 14, 2012

News Daily News

No hay una Ventana Segura para la Terapia Antitrombótica Triple en Pacientes con FA de Alto Riesgo

August 14, 2012

News Daily News

Indirect Comparisons Show Little Difference Among New Anticoagulants

August 14, 2012

News Daily News

Comparativas Indirectas revelan que hay Pocas Diferencias entre Nuevos Anticoagulantes

August 14, 2012

News Daily News

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

L.A. McKeown

August 09, 2012

News Daily News

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

L.A. McKeown

August 09, 2012

News Daily News

La Anticoagulación Protege a aquellos Pacientes con FA que se someten a PCI, a pesar del Riesgo Hemorrágico

Caitlin E. Cox

July 16, 2012

News Daily News

Anticoagulation Protects A-Fib Patients Undergoing PCI, Despite Bleeding Risk

Caitlin E. Cox

July 16, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

L.A. McKeown

June 06, 2012

Presentation

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: S. Lee

June 05, 2012

Advertisement

New Class of Oral Anticoagulants Safer Compared with Warfarin for A-fib

El Apixaban tiene el Mismo Riesgo Hemorrágico que la Aspirina en Pacientes con FA

Apixaban Matches Bleeding Risk of Aspirin in A-fib Patients

El Apixaban Supera a la Warfarina a Todos los Niveles de Riesgo en Pacientes con FA

Apixaban Surpasses Warfarin At All Risk Levels in A-Fib Patients

JACC Viewpoint: Studies Needed on Long-term Consequences of ‘Silent’ Cerebral Infarcts

Dabigatran Usage up, Both for A-fib and Off-Label Indications

No Safe Window for Triple Antithrombotic Therapy in High-Risk A-fib Patients

No hay una Ventana Segura para la Terapia Antitrombótica Triple en Pacientes con FA de Alto Riesgo

Indirect Comparisons Show Little Difference Among New Anticoagulants

Comparativas Indirectas revelan que hay Pocas Diferencias entre Nuevos Anticoagulantes

Updated Guidelines Support New Antithrombotics as Warfarin Alternatives in A-fib

Las Directrices Actualizadas Avalan los Nuevos Antitrombóticos como Alternativas a la Warfarina contra la FA

La Anticoagulación Protege a aquellos Pacientes con FA que se someten a PCI, a pesar del Riesgo Hemorrágico

Anticoagulation Protects A-Fib Patients Undergoing PCI, Despite Bleeding Risk

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Rivaroxaban May be Cost-Effective for A-fib Patients

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

Cost-effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content